Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 4

Prospective Multicenter Clinical Performance Study of a Single-use Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories

NCT ID: NCT07120295Sponsor: University of Colorado, DenverLast updated: 2025-09-05

Summary

This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. This includes achieving stone fragmentation of difficult biliary stone(s) while obtaining adequate tissue specimens for analysis. There will also be a Product performance evaluation as rated by the endoscopist operating the DPS System and evaluation of ergonomics and usability.

Arms & interventions

  • DeviceDragonfly™ Digital Pancreaticobiliary System

    Dragonfly™ Digital Pancreaticobiliary System is indicated for use in the direct visualization of the biliary and pancreatic ducts for diagnostic and therapeutic interventions during endoscopic procedures. DPS is a single-use device that serves as an access and delivery catheter used with a proprietary DDC. The DDC is intended to control auto-illumination, and process images from the DPS for diagnostic and therapeutic applications during endoscopic procedures in the pancreaticobiliary system including the hepatic ducts.

Outcome measures

Primary

  • Stone Fragmentation- Clearing of Biliary Stones

    Will evaluate the effectiveness of digital cholangioscopy (DC) in guiding fragmentation of difficult biliary stones. Will examine the efficacy of the intraductal lithotripsy procedure utilizing electrohydraulic lithotripsy in achieving biliary stone fragmentation and complete bile duct stone clearance among patients who have failed conventional stone extraction techniques. Stone fragmentation and complete ductal clearance will be assessed using descriptive statistics with interquartile range (IQR) for the number of procedures to achieve clearance at index or subsequent procedures. Ninety-five percent confidence intervals will be provided for descriptive statistics.

    Time frame: Up to 6 months

  • Tissue Acquisition during endoscopy procedure

    Will evaluate the ability of the DC to deliver tools to obtain adequate tissue samples (biopsies) to be analyzed for the presence or absence of disease, including cancer, infection, or other conditions in subjects with indeterminate strictures. Will use descriptive analysis with sensitivity, specificity, accuracy, median and IQR plus operating characteristics of visualization and sampling in those patients with indeterminate strictures. Will evaluate the diagnostic efficacy of the novel biopsy forceps in the context of indeterminate biliary strictures and provide robust evidence for clinical decision-making.

    Time frame: Up to 6 months

Secondary

  • Total procedure time

    Time frame: Up to 6 months

  • Product performance evaluation as rated by the endoscopist operating the DPS System

    Time frame: Up to 6 months

  • DPS Functionality during Endoscopy Procedures

    Time frame: Up to 6 months

  • Ergonomics

    Time frame: Up to 6 months

  • Lithotripsy fragmentation time

    Time frame: Up to 6 months

  • Product Performance

    Time frame: Up to 6 months

  • Usability

    Time frame: At the completion of the study

  • Visualization of biliary strictures

    Time frame: Up to 6 months

  • Visualization of stone or stricture characteristics

    Time frame: Up to 6 months

  • User satisfaction

    Time frame: At the completion of the study

  • Passing of device to target area

    Time frame: Up to 6 months

  • Work

    Time frame: After each case

  • Bile duct stone recurrence rate

    Time frame: At 6 months

Eligibility criteria

Sex: AllAge: 21 Years and olderHealthy volunteers: No
Inclusion Criteria: 1. Provision to sign and date the consent form; 2. Adult patients ≥ 21 years old; 3. Any patient who is required to undergo endoscopic retrograde cholangiopancreatography (ERCP) procedure with the clinical need to perform cholangioscopy for: 1. Indeterminate biliary stricture, or 2. Failed biliary stone extraction with conventional techniques. 4. Willing and able to follow study procedures and comply with study follow-up. Exclusion Criteria: 1. Pregnancy or lactation; 2. Surgically or physiologically altered GI anatomy that precludes advancement of the duodenoscope for biliary cannulation; 3. Patients on anti-coagulants and anti-platelet medications that cannot be withheld pre-procedure, except for aspirin, 81mg; 4. Coagulopathy (INR \> 1.8) or thrombocytopenia (Platelets \< 50,000) that is not correctable and felt to be a contraindication to proceeding with biopsy or lithotripsy per the treating endoscopist; 5. Active suppurative cholangitis with evidence of purulent drainage at the time of papilla visualization; 6. Patients who are not candidates for anesthesia to permit ERCP.

Study locations (1)

Universtiy of Colorado Hospital

Aurora, Colorado, 80045

Recruiting
Inga Cuba Research Manager · Contact
Sandra Boimbo DART Program Director · Contact
Raj Shah, MD · Principal Investigator
Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | Cancerify